G1 Therapeutics to Provide Fourth Quarter and Full Year 2020 Financial Results and Business Update on February 24, 2021
RESEARCH TRIANGLE PARK, N.C., Feb. 17, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: ), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the fourth quarter and full year of 2020 on Wednesday, February 24, 2021 at 4:30 p.m. ET.
The live call may be accessed by dialing (866) 763-6020 (domestic) or (210) 874-7713 (international) and entering the conference code: 5267698. The live and archived webcast will be available on the of
About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product COSELA™ (trilaciclib). G1 has a deep clinical pipeline evaluating targeted cancer therapies in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit and follow us on Twitter .
Contact:
Will Roberts
G1 Therapeutics, Inc.
Vice President, Investor Relations & Corporate Communications
(919) 907-1944
